Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Journal of Environmental Pathology, Toxicology and Oncology
Factor de Impacto: 1.625 Factor de Impacto de 5 años: 1.63 SJR: 0.402 SNIP: 0.613 CiteScore™: 2.3

ISSN Imprimir: 0731-8898
ISSN En Línea: 2162-6537

Journal of Environmental Pathology, Toxicology and Oncology

DOI: 10.1615/JEnvironPatholToxicolOncol.v21.i2.90
10 pages

Novel Approaches for Colon Cancer Prevention by Cyclooxygenase-2 Inhibitors

Bandaru S. Reddy
Nutritional Carcinogenesis and Chemoprevention Program, American Health Foundation, Valhalla, NY 10595
Chinthalapally V. Rao
Nutritional Carcinogenesis and Chemoprevention Program, American Health Foundation, Valhalla, NY 10595

SINOPSIS

During recent years, multidisciplinary studies in epidemiology and molecular biology, as well as preclinical studies, have contributed much to our understanding of the etiology of colorectal cancer; more importantly they have enabled us to approach its prevention. An impressive body of epidemiological data suggests an inverse relationship between colorectal cancer risk and regular use of nonsteroidal antiinflammatory drugs (NSAIDs), including aspirin. Clinical trials with NSAIDs have demonstrated that NSAID treatment caused regression of preexisting colon adenomas in patients with familial adenomatous polyposis. Preclinical efficacy studies have provided compelling evidence that several phytochemicals with antiinflammatory properties and NSAIDs act to retard, block, or reverse colon carcinogenesis. Equally exciting are opportunities for effective chemoprevention with selective cyclooxygenase-2 (COX-2) inhibitors including celecoxib and rofecoxib in a variety of preclinical models of colon cancer. Naturally occurring COX-2 inhibitors such as curcumin and certain phytosterols have been proven to be effective as chemopreventive agents against colon carcinogenesis with minimal gastrointestinal toxicity. Multistep process of carcinogenesis has provided substantial insights into the mechanisms by which naturally occurring and synthetic antiinflammatory agents modulate these events leading to suppression of tumorigenesis. Growing knowledge in this area has brought about innovative approaches using a combination of agents with different modes of action as a means of increasing efficacy and minimizing toxicity. The natural history of colorectal cancer, from dysplastic aberrant crypts to adenomas and adenocarcinomas, offers multiple opportunities for assessment and intervention. Of further importance would be to identify molecular targets that are critical in the growth and survival of the malignant colorectal cell and are modulated by NSAIDs and COX-2 inhibitors.


Articles with similar content:

Immunocytokines for Cancer Therapy
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 1-2
Dario Neri, Philipp Probst
Precise Diagnosis and Treatment of Thymic Epithelial Tumors Based on Molecular Biomarkers
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 5-6
Jun Du, Xiao-Jun Zhou
Biomarkers of DNA Repair and Related Pathways: Significance of Treatment in Triple-Negative Breast Cancer
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 5-6
Wenwen Guo, Xue He, Congyang Wang, Nannan Chen, Yan Wang, Fengxia He, Li Lin
Inhibitors of Cell Cycle Kinases: Recent Advances and Future Prospects as Cancer Therapeutics
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 2
Robert L. Sutherland, Andrew Stone, Elizabeth A . Musgrove
Venoms Can Be a Boon for Cancer Patients
Forum on Immunopathological Diseases and Therapeutics, Vol.4, 2013, issue 3-4
Sudhir Kumar, Ruchi Jain, Puja Sarkar